Terumo (JP:4543) has released an update. Terumo Corporation has decided to buy back up to 15 million of its own shares for a maximum of 30 billion …

Terumo (JP:4543) has released an update. Terumo Corporation intends to conduct a secondary offering of its common stock to diversify and expand its…

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM ) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024 . Significant Near and Short Term Value Enhancing Catalysts U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected Q4 2024. The purpose of the meeting is to obtain independent expert advice on scientific, technical, and policy matters related to the Company''s De Novo Marketing Clearance Request for a minimally invasive alternative treatment for women diagnosed with early-stage, low risk breast cancer. The FDA will review and evaluate the recommendation of the Medical Device Advisory Committee and is expected to have a final decision regarding marketing clearance of ProSense® in early-stage, low risk breast cancer by early 2025.

Q1 2025 Terumo Corp Earnings Presentation Transcript

Terumo (TRUMF) reports Q1 revenue of 258,194M Yen and EPS of 22.82 Yen in their latest financial results press release.

TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading…

Terumo launches $75M venture fund, Terumo Ventures, to invest in early-stage medtech companies. Explore how this strategic move aligns with their growth strategy and vision for healthcare innovation.

TOKYO, Aug. 5, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading the Group''s venture investments, as a department within Terumo Americas Holding, Inc. Terumo…

Terumo (JP:4543) has released an update. Terumo Corporation has completed the sale of treasury shares as restricted stock remuneration on August 2,…

Terumo (JP:4543) has released an update. Terumo Corporation has completed the setup of its No.12 Share Warrant issuance, allocating a total of 4,04…